LC-MS/MS comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-08-07. Numbers and descriptions here follow the published literature rather than marketing material.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
Laboratory detection of cardarine typically involves sample preparation followed by chromatographic separation and mass spectrometric identification. Urine is the most common matrix for anti-doping tests, though blood and hair have also been explored. Methods can target the parent compound or its metabolites, depending on the expected window of detection. Reference standards are required for accurate quantification. Matrix effects and dilution can influence results, so laboratories use internal standards and validation protocols. The exact detection window varies with dose, route, and individual metabolism.
A common misconception is that cardarine has been proven safe for human use. In reality, human clinical data are limited, and long-term animal studies have raised concerns about cancer. Another misconception is that it is a supplement or vitamin-like compound. It is a synthetic research chemical with no approved medical indication. Scientific discussion often focuses on its mechanism and detection rather than therapeutic use. Regulatory and anti-doping literature treats it primarily as a prohibited substance.
| Property | Value | Notes |
|---|---|---|
| Chemical class | PPARδ agonist | Not an anabolic steroid. |
| Common synonyms | GW501516, GW-1516 | Cardarine is an informal name. |
| Appearance | White to off-white powder | Typical for research-grade solid. |
| Solubility class | Poorly soluble in water; soluble in some organic solvents | Such as DMSO or ethanol in laboratory settings. |
| Typical storage temperature | Cool, dry, protected from light | Specific conditions vary by supplier and form. |
Handling and quality assessment of cardarine reference material follow general laboratory practices for poorly characterized compounds. It typically appears as a white to off-white powder and is sparingly soluble in water but soluble in organic solvents such as dimethyl sulfoxide and ethanol. Storage recommendations usually specify a cool, dry, dark place, with long-term storage at low temperature and desiccation. Purity may be checked by high-performance liquid chromatography with ultraviolet detection, while identity is confirmed by mass spectrometry and nuclear magnetic resonance. No pharmacopeial monograph exists, so reported purity and stability depend on the supplier’s methods.
GW501516 acts as a selective agonist at PPARδ, a nuclear receptor that regulates transcription of genes involved in lipid handling and energy metabolism. Activation of PPARδ in preclinical models increases fatty acid oxidation, mitochondrial biogenesis, and exercise endurance in rodents. These effects have made the compound a subject of metabolic research and also a target for sport anti-doping rules. In humans, however, controlled studies are limited, and whether similar endurance or metabolic changes occur at tolerated exposures remains an open question. The receptor’s broad tissue distribution also means downstream effects may vary by organ and condition.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Products sold as cardarine have been found to contain incorrect compounds, variable amounts, or no active ingredient at all. Independent testing is required to verify identity and purity. Common analytical approaches include high-performance liquid chromatography, mass spectrometry, and nuclear magnetic resonance for structural confirmation. These methods can distinguish GW501516 from related PPAR agonists and from unrelated steroids. For regulators and researchers, such verification is central to interpreting both biological results and adverse event reports.
Cardarine is prohibited in competitive sport under the World Anti-Doping Agency code, where it is classified as a metabolic modulator. It is not approved as a prescription medicine in the United States, European Union, or other major markets. Regulatory action has focused on its presence in sports and in products marketed as research chemicals. Because it has no accepted medical indication, supply is often unregulated. This status creates legal and safety uncertainties for anyone who encounters the substance.
Anti-doping laboratories detect GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be used in some programs. Detection depends on factors such as dose, timing, metabolism, and the sensitivity of the assay. Published methods describe limits of detection in the low nanogram per milliliter range for related compounds. Exact detection windows are not fixed for all situations and remain an area of ongoing study.
Published literature on cardarine includes in vitro assays, rodent experiments, and a small number of human studies. Reports describe effects on exercise capacity and lipid metabolism in animals, while human evidence is sparse. Many online descriptions present the compound as a proven endurance aid, a claim not supported by regulatory approval or large clinical trials. Analytical studies focus on identifying the parent compound and its metabolites in biological samples. Important uncertainties include species differences, dose-response relationships, and the relevance of rodent tumor findings to humans.
Cardarine is the common name for GW501516, a synthetic compound studied as a peroxisome proliferator-activated receptor delta agonist. Researchers developed it to explore treatments for lipid disorders and metabolic conditions. It is not an approved medicine in any country. Early clinical work examined changes in HDL cholesterol and triglycerides, but development was discontinued after animal studies raised concerns about cancer. The compound remains available as a research chemical and appears in discussions of performance enhancement.
At the molecular level, GW501516 binds and activates PPARδ, a nuclear receptor that regulates transcription. Activation shifts expression of genes involved in fatty acid oxidation, energy expenditure, and lipid transport in skeletal muscle and liver. Animal studies report increased endurance and altered lipid profiles after exposure. Human data are limited to small trials and do not establish long-term safety or efficacy. PPARδ also has roles in cell proliferation, so the relationship between activation and cancer risk remains an open question.
C. Judson King is an American chemical engineer, researcher, administrator and educator. He is professor emeritus at University of California, Berkeley, and UC universitywide provost and senior vice president of academic affairs, emeritus, at University of California. He is the former director of Center for Studies in Higher Education and the former dean of College of Chemistry at UC Berkeley. King's research has been focused in two areas: chemical engineering and higher education. In the area of chemical engineering, he has conducted considerable research on spray drying, freeze drying, and removal and recovery of organic pollutants from wastewater streams. In the area of higher education he has written about university structure and governance, innovation in universities, and engineering education. He has written three books and over 250 scientific articles. He holds 13 patents. King has received many awards for his contribution to the field of chemical engineering. He was elected to the National Academy of Engineering in 1981 for distinguished contributions to freeze-drying technology, systematic studies of chemical-process synthesis, and chemical engineering education. He became a fellow of the American Institute of Chemical Engineers in 1983, and a fellow of the American Association for the Advancement of Science in 1993. In 2009, the American Institute of Chemical Engineers named him one of the 100 Chemical Engineers of the Modern Era.
=== Fluorescent dye uses === Colorless fluorescent dyes that emit blue light under UV are added as optical brighteners to paper and fabrics. The blue light emitted by these agents counteracts yellow tints that may be present and causes the colors and whites to appear whiter or more brightly colored. UV fluorescent dyes that glow in the primary colors are used in paints, papers, and textiles either to enhance color under daylight illumination or to provide special effects when lit with UV lamps. Blacklight paints that contain dyes that glow under UV are used in a number of art and aesthetic applications.
=== Inclusion of clothing and personal effects === The body may be dressed in fancy and/or ceremonial clothes. Personal objects of the deceased, such as a favorite piece of jewelry or photograph, may be included with the body. This practice, also known as the inclusion of grave goods, serves several purposes:
== India == 7-Eleven - Just in Metro Cities Central Bazaar - National Player DMart - National Player HyperCity - Just in Metro cities Kurinji Metro Bazaar - Regional Player Lulu Hypermarket - Just in Metro Cities Maveli Stores - Regional Player More - Regional Player Namdhari's Fresh - Regional Player Nesto - Regional Player Nilgiri's - Regional Player Reliance Fresh - National Player Smart Bazaar - National Player Spar - In Metro cities Spencer's Retail - Regional Player Triveni Supermarkets - Regional Player Valuezone Hypermarket - Regional Player Walmart - Just in Metro Cities
Sources: en.wikipedia.org
=== Unknown blood type === Because blood type O negative is compatible with anyone, it is often overused and in short supply. According to the Association for the Advancement of Blood and Biotherapies, the use of this blood should be restricted to persons with O negative blood, as nothing else is compatible with them, and women who might be pregnant and for whom it would be impossible to do blood group testing before giving them emergency treatment. Whenever possible, the AABB recommends that O negative blood be conserved by using blood type testing to identify a less scarce alternative.
=== Type 1 PSSM === Type 1 PSSM is caused by an autosomal dominant genetic mutation known as GSY1. This mutation causes an up-regulation of glycogen synthase, and high levels of glycogen synthase relative to glycogen branching enzyme (GBE). This altered ratio of glycogen synthase to GBE results in glycogen molecules with long chains and few branches, making these molecules somewhat resistant to amylase breakdown on amylase-PAS (periodic acid-Schiff) stained biopsies. The GSY1 mutation is associated with altered glucose metabolism (but normal glycogen metabolism), as well as accumulation of high levels of glycogen and abnormal polysaccharide in the muscles of the horse. Additionally, some horses have been shown to have insulin sensitivity, which improves glucose uptake by muscle cells and contributes to excessive glycogen storage that is already elevated secondary to the GSY1 mutation.
==== 1500–1599 ==== Local Authorities' Traffic Orders (Procedure) (England and Wales) (Amendment) Regulations 1993 (S.I. 1993/1500) A4074 Trunk Road (Crowmarsh Bypass) (Detrunking) Order 1993 (S.I. 1993/1501) Education (School Information)(England) Regulations 1993 (S.I. 1993/1502) Education (School Performance Information) (England) Regulations 1993 (S.I. 1993/1503) Non-Domestic Rating Contributions (Wales) (Amendment) Regulations 1993 (S.I. 1993/1505) Non-Domestic Rating (Demand Notices) (Wales) (Amendment) Regulations 1993 (S.I. 1993/1506) Value Added Tax (Supply of Services) Order 1993 (S.I. 1993/1507) Rent Act 1977 (Forms etc.) (Welsh Forms and Particulars) Regulations 1993 (S.I. 1993/1511) Non-Domestic Rating Act 1993 (Commencement No. 2) Order 1993 (S.I. 1993/1512) Food Protection (Emergency Prohibitions) (Paralytic Shellfish Poisoning) (No.5) Order 1993 (S.I. 1993/1515) Charging Orders (Residential Accommodation) (Scotland) Order 1993 (S.I. 1993/1516) Financial Assistance for Environmental Purposes (No. 2) Order 1993 (S.I. 1993/1518) Egg Products Regulations 1993 (S.I. 1993/1520) Gas (Meters) (Amendment) Regulations 1993 (S.I. 1993/1521) Northern Ireland (Emergency and Prevention of Terrorism Provisions) (Continuance) Order 1993 (S.I. 1993/1522) Food Protection (Emergency Prohibitions) (Paralytic Shellfish Poisoning) (No.6) Order 1993 (S.I. 1993/1523) Education (School Inspection) (Wales) Regulations 1993 (S.I. 1993/1529) Cosmetic Products (Safety) (Amendment)Regulations 1993 (S.I. 1993/1539) Income-related Benefits Schemes (Miscellaneous Amendments) (No.
Alpha-fetoprotein (AFP, α-fetoprotein; also sometimes called alpha-1-fetoprotein, alpha-fetoglobulin, or alpha fetal protein) is a protein that in humans is encoded by the AFP gene. The AFP gene is located on the q arm of chromosome 4 (4q13.3). Maternal AFP serum level is used to screen for Down syndrome, neural tube defects, and other chromosomal abnormalities. AFP is a major plasma protein produced by the yolk sac and the fetal liver during fetal development. It is thought to be the fetal analog of serum albumin. AFP binds to copper, nickel, fatty acids and bilirubin and is found in monomeric, dimeric and trimeric forms.
== Function == SPINK functions as a competitive inhibitor of trypsin, which is a protease that can activate other proteases. It has been shown to prevent premature activation of pancreatic enzymes. Monitor peptide binds to intestinal epithelial cells and induces CCK-release, which enhances pancreatic secretion in the presence of nutritional protein in the duodenum. When all nutritional protein is digested, monitor peptide is bound by trypsin and subsequently degraded, resulting in decreasing CCK-release and a reduction of pancreatic secretion. Similar to CCK-releasing peptide (CCK-RP, homologous to DBI), it is trypsin sensitive and stimulates CCK release. It is possible that it also stimulates the growth of intestinal epithelial cells.
Sources: en.wikipedia.org
Cardarine is commonly known as GW501516 or GW-1516. These names refer to the same synthetic compound. It is not a brand-name approved medicine.
No, cardarine is not a steroid. It is classified as a PPARδ agonist. Its structure and receptor target differ from anabolic steroids.
No regulatory agency has approved cardarine as a medicine. It was investigated in early research but development was discontinued. It is not available as a prescription drug.
Yes, WADA prohibits cardarine as a PPARδ agonist. It appears on the prohibited list and can be detected in urine or blood. Athletes using it risk sanctions.